President Donald Trump in a press conference on Thursday said the Food and Drug Administration is fast-tracking efforts to approve an antiviral therapy, best known for treating malaria, for use in coronavirus cases. 

The drug, hydroxychloroquine, was developed more than a half-century ago and is approved for treating malaria, arthritis, and other ailments. Reports out of China and Italy suggest the drug may help, but there is no hard data yet.

"We're going to be able to make that drug available almost immediately," Trump said. 

The FDA is working to conduct a "large, pragmatic clinical trial" quickly to confirm the drug's benefit to coronavirus patients, said Commissioner Dr. Stephen Hahn.

He also tempered the president's optimism about the still-untested solution. 

"What's also important is not to provide false hope," he said. "We may have the right drug, but it might not be in the appropriate dosage form right now, and it might do more harm than good."

New antiviral therapies face a shorter and less arduous approval process than vaccines, several of which are under development with 12 to 18-month timelines.  

"The therapies are something we could move on much faster potentially," Trump said. 

He claimed the administration "slashed red tape" to develop new vaccines and therapies.

The president also held out on confirming whether he would invoke the Defense Production Act, which he signed on Wednesday, to mandate the production of needed medical supplies such as N95 respirators and surgical masks

"If we find that we need something, then we will do that," he said.  

Trump repeated that he was open to the federal government buying equity stakes in the airline, cruise, hospitality, and other industries hurt by the outbreak. 

The press conference opened with more controversial language placing the blame squarely on China for the outbreak, despite concerns voiced about potentially exacerbating a backlash against Asian Americans.

"We continue our relentless effort to defeat the Chinese virus," Trump said.

Share:
More In Politics
Poll Finds Racial Splits on Worries Over COVID-19 Pandemic
An recently conducted AP-NORC poll found that majorities of the Black and Hispanic populations in the U.S. still find themselves either somewhat worried or extremely worried over the pandemic, while more than half of white Americans responded with either being not too worried or not worried at all. Dr. Chris Pernell, the chief strategic integration and health equity officer at University Hospital, joined Cheddar News to talk about how perceptions of COVID-19 differ between groups of Americans. "We’re still seeing people get infected, and because of the toll of the disproportionate impact, we have concerns among the Black and brown community about whether or not they have an increased risk of exposure because of where they work, because of the use of public transportation, because they live in homes that they may not be able to safely quarantine and or isolate in, and because they have at baseline chronic health conditions that may make coronavirus more severe in those persons," she said.
Calif. Probes ExxonMobil Over Accusations of Lying About Plastic Recycling
Judith Enck, a former regional administrator for the EPA and the president of Beyond Plastics, joined Cheddar News to talk about the role of plastics in the climate crisis and California's investigation of ExxonMobil and other oil companies for misleading the public on the ability to recycle plastics. "The reason why petrochemical companies like Exxon have gotten away with selling more and more plastic is that they've lied to the public and told us don't worry about all those negative upstream impacts and downstream impacts of plastics. Just be sure to recycle it. Well, guess what? Plastics largely are not recycled," Enck said.
Volatile 'Mixed Bag' Market Conditions Appear Hard to Read
The ongoing war in Ukraine and the Fed's hawkish stance toward reining in inflation might be causing a frenzy among investors. Craig Erlam, a senior market analyst at foreign exchange OANDA, joined Cheddar News to talk about the current "mixed bag" markets. "It's hard to read too much into it. These are just the market conditions we have right now," he said. "Ultimately we're a little directionless at times overall, but these intraday moves are causing a lot of volatility this week."
Need2Know: Ukraine Aid Package, GDP Shrinks & Beijing Lockdown
Catching you up on what you need to know on April 29, 2022, with President Biden asking Congress for a $33 billion aid package for Ukraine, a shrinking GDP potentially leading to a recession, Beijing banning weddings and funerals while closings schools amid COVID, and more.
First-Time Homebuyers Face Rising Mortgage Rates
Buying a new home is tough right now; but for first-time buyers, it's an especially challenging time, with obstacles like rising mortgage rates and record-breaking home prices. The housing market is not expected to get much friendlier, as mortgage rates are expected to continue to climb as the Federal Reserve proceeds with its plans for rate hikes in an effort to stifle inflation. Jonathan Miller, President and CEO of real estate appraiser Miller Samuel, joins Cheddar News' Closing Bell to discuss.
Title 42: What It Is and Why It's Such a Big Deal
Tyler Moran, former senior adviser to President Biden on migration, joins Cheddar Politics to discuss the recent controversy around the administration's decision to end the use of Title 42, a public health order allowing the U.S. to expel migrants without going through the asylum process.
Biden Targets 'Ghost Guns' with New Executive Action
Christian Heyne, vice president of policy at the gun safety group Brady, joins Cheddar Politics to discuss President Biden's executive action on so-called "ghost guns," and to reflect on the Brooklyn subway shooting.
Load More